Technology ID
E-202-2011-0

Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities

Linked ID
TAB-2330
Inventors
Andrei Pomerantsev (NIAID)
Stephen Leppla (NIAID)
Lead Inventors
Andrei Pomerantsev (NIAID)
Co-Inventors
Stephen Leppla (NIAID)
Development Status
  • Early-stage
  • In vitro data available
Therapeutic Areas
Infectious Disease
ICs
NIAID
Commercial Applications
  • Vaccine production
  • Recombinant protein production
  • B. anthracis vaccine production
Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin and ability to fold proteins correctly. This application claims a B. anthracis strain in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield.
Competitive Advantages
  • Highly efficient production of recombinant proteins
  • Low cost production of recombinant proteins

Request More Info

Licensing Contact